Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial

Laurie E. Steffen McLouth, Fengmin Zhao, Taofeek K. Owonikoko, Josephine L. Feliciano, Nisha A. Mohindra, Suzanne E. Dahlberg, James L. Wade, Gordan Srkalovic, Bradley W. Lash, Joseph W. Leach, Ticiana A. Leal, Charu Aggarwal, David Cella, Suresh S. Ramalingam, Lynne I. Wagner

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial'. Together they form a unique fingerprint.

Medicine & Life Sciences